221 related articles for article (PubMed ID: 23136837)
1. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
Roach RE; Lijfering WM; Helmerhorst FM; Cannegieter SC; Rosendaal FR; van Hylckama Vlieg A
J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
Archer DF; Oger E
Climacteric; 2012 Jun; 15(3):235-40. PubMed ID: 22612609
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
4. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
van Hylckama Vlieg A; Helmerhorst FM; Vandenbroucke JP; Doggen CJ; Rosendaal FR
BMJ; 2009 Aug; 339():b2921. PubMed ID: 19679614
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
6. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Połać I; Borowiecka M; Wilamowska A; Nowak P
Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
Canonico M
Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.
Sweetland S; Beral V; Balkwill A; Liu B; Benson VS; Canonico M; Green J; Reeves GK;
J Thromb Haemost; 2012 Nov; 10(11):2277-86. PubMed ID: 22963114
[TBL] [Abstract][Full Text] [Related]
10. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
11. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
[TBL] [Abstract][Full Text] [Related]
12. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
13. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
14. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy and venous thromboembolism among postmenopausal women.
Scarabin PY
Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
[TBL] [Abstract][Full Text] [Related]
16. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
Scarabin PY
Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359
[TBL] [Abstract][Full Text] [Related]
17. Estrogen plus progestin and risk of venous thrombosis.
Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
[TBL] [Abstract][Full Text] [Related]
18. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.
Lundström E; Virijevic I; Söderqvist G
Horm Mol Biol Clin Investig; 2020 Jul; 41(3):. PubMed ID: 32735552
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
20. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
Speroff L
Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
